{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:56:28Z","timestamp":1771656988290,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.pupt.2006.06.003","type":"journal-article","created":{"date-parts":[[2006,7,12]],"date-time":"2006-07-12T14:03:06Z","timestamp":1152712986000},"page":"571-579","source":"Crossref","is-referenced-by-count":26,"title":["Cardiac safety of formoterol 12\u03bcg twice daily in patients with chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"20","author":[{"given":"Sammy C.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard J.","family":"Criner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard E.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadwick J.","family":"Orevillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Ziehmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2006.06.003_bib1","unstructured":"Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256\u201376 (updated 2003. Available at http:\/\/www.goldcopd.com. Accessed August 4, 2004."},{"key":"10.1016\/j.pupt.2006.06.003_bib2","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1378\/chest.123.5.1684","article-title":"Interpreting COPD prevalence estimates: what is the true burden of disease?","volume":"123","author":"Halbert","year":"2003","journal-title":"Chest"},{"issue":"2 Suppl","key":"10.1016\/j.pupt.2006.06.003_bib3","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1378\/chest.117.2_suppl.5S","article-title":"The economic burden of COPD","volume":"117","author":"Sullivan","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2006.06.003_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD","volume":"125","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2006.06.003_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1155\/2002\/604092","article-title":"Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study","volume":"9","author":"Kottakis","year":"2002","journal-title":"Can Respir J"},{"key":"10.1016\/j.pupt.2006.06.003_bib6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1034\/j.1399-3003.1999.13e27.x","article-title":"Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease","volume":"13","author":"Maesen","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2006.06.003_bib7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1159\/000029427","article-title":"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action","volume":"66","author":"Celik","year":"1999","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2006.06.003_bib8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/rmed.2001.1161","article-title":"Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil\u00ae Aerolizer\u2122) with salbutamol (Ventodisk\u2122)","volume":"95","author":"Benhamou","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2006.06.003_bib9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2006.06.003_bib10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1378\/chest.121.4.1058","article-title":"For the Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD","volume":"121","author":"Rossi","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2006.06.003_bib11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1742-1241.2003.tb10590.x","article-title":"State of the art in \u03b22-agonist therapy: a safety review of long-acting agents","volume":"57","author":"Rabe","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pupt.2006.06.003_bib12","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","article-title":"Cardiovascular effects of \u03b2-agonists in patients with asthma and COPD. A meta-analysis.","volume":"125","author":"Salpeter","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2006.06.003_bib13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/clc.4960200711","article-title":"Atrial fibrillation: a review of mechanism, etiology, and therapy","volume":"20","author":"Mackstaller","year":"1997","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pupt.2006.06.003_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0025-7125(05)70324-2","article-title":"Proarrhythmia","volume":"85","author":"Naccarelli","year":"2001","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.pupt.2006.06.003_bib15","first-page":"S77","article-title":"Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease","volume":"152","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2006.06.003_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0002-9149(87)80078-4","article-title":"Application of a frequency definition of ventricular proarrhythmia","volume":"59","author":"Morganroth","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pupt.2006.06.003_bib17","doi-asserted-by":"crossref","first-page":"89B","DOI":"10.1016\/0002-9149(84)90509-5","article-title":"Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram","volume":"53","author":"Morganroth","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pupt.2006.06.003_bib18","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/eurheartj\/ehi291","article-title":"Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease","volume":"26","author":"Rutten","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pupt.2006.06.003_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.annepidem.2005.04.008","article-title":"Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients","volume":"16","author":"Curkendall","year":"2006","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.pupt.2006.06.003_bib20","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1378\/chest.128.4.2640","article-title":"Cardiovascular morbidity and mortality in COPD","volume":"128","author":"Huiart","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2006.06.003_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1081-1206(10)62351-4","article-title":"A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler","volume":"86","author":"Bensch","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.pupt.2006.06.003_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1081\/JAS-120018780","article-title":"Formoterol delivered via the dry powder Aerolizer\u00ae inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial","volume":"40","author":"Pleskow","year":"2003","journal-title":"J Asthma"},{"key":"10.1016\/j.pupt.2006.06.003_bib23","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1378\/chest.123.6.1817","article-title":"Cardiovascular safety of salmeterol in COPD","volume":"123","author":"Ferguson","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2006.06.003_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.114.2.411","article-title":"Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia","volume":"114","author":"Cazzola","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2006.06.003_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2004.03.048","article-title":"Association between chronic heart failure and inhaled \u03b2-2-adrenoceptor agonists","volume":"148","author":"Au","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.pupt.2006.06.003_bib26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s002280050478","article-title":"Concomitant inhaled corticosteroid resensitises cardiac beta2-adrenoceptors in the presence of long-acting beta2-agonist therapy","volume":"54","author":"Aziz","year":"1998","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455390600068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455390600068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T01:27:57Z","timestamp":1683509277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109455390600068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S109455390600068X"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2006.06.003","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}